[1] Rainusso N, Brawley VS, Ghazi A, et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumorinitiating cells in osteosarcoma[J]. Cancer Gene Ther, 2012, 19(3): 212-217.
[2] Daft PG, Yuan K, Warram JM, et al. AlphaCaMKII plays a critical role in determining the aggressive behavior of human osteosarcoma[J]. Mol Cancer Res, 2013, 11(4): 349-359.
[3] Baamonde A, CurtoReyes V, Juárez L, et al. Antihyperalgesic effects induced by the IL1 receptor antagonist anakinra and increased IL1 beta levels in inflamed and osteosarcomabearing mice[J]. Life Sci, 2011, 81(8): 673-682.
[4] Liebau C, Roesel C, Schmidt S, et al. Immunotherapy by gene transfer with plasmids encoding IL12/IL18 is superior to IL23/IL18 gene transfer in a rat osteosarcoma model[J]. Anticancer Res, 2004, 24(5A): 2861-2867.
[5] Strander H. Interferons and osteosarcoma[J]. Cytokine Growth Factor Rev, 2007, 18(56): 373380.
[6] Fulda S, Debatin KM. 5Aza2′deoxycytidine and IFNgamma cooperate to sensitize for TRAILinduced apoptosis by upregulating caspase8[J]. Oncogene, 2006, 25(37): 5125-5133.
[7] Gauthaman K, Fong CY, Arularasu S, et al. Human Wharton′s jelly stem cell conditioned medium and cellfree lysate inhibit human osteosarcoma and mammary carcinoma cell growth in vitro and in xenograft mice[J]. J Cell Biochem, 2013, 114(2): 366-377.
[8] Wang YC, Zheng LH, Ma BA, et al. Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma[J]. Acta Histochem, 2011, 113(4): 402-408.
[9] Tsang WP, Chau SP, Fung KP, et al. Modulation of multidrug resistanceassociated protein 1 (MRP1) by p53 mutant in Saos2 cells[J]. Cancer Chemother Pharmacol, 2003, 51(2): 161-166.
[10] Xie XK, Yang DS, Ye ZM, et al. Construction of antisense cmyc recombinant adenovirus and its antitumor effects on osteosarcoma cell lines MG63 and U2OS[J]. Ai Zheng, 2005, 24(3): 292-297.
[11] Martelli L, Di Mario F, Botti P, et al. Accumulation, platinumDNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wildtype status[J]. Biochem Pharmacol, 2007, 74(1): 20-27.
[12] Ketola A, Mtt AM, Pasanen T, et al. Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase/ganciclovir gene therapy[J]. Int J Mol Med, 2004, 13(5): 705-710.
[13] Seto M, Yamazaki T, Sonoda J, et al. Suppression of tumor growth and pulmonary metastasis in murine osteosarcoma using gene therapy[J]. Oncol Rep, 2002, 9(2): 337-340.
[14] Oosterhoff D, Witlox MA, van Beusechem VW, et al. Genedirected enzyme prodrug therapy for osteosarcoma: sensitization to CPT11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase2[J]. Mol Cancer Ther, 2003, 2(8): 765-771.
[15] Lafleur EA, Jia SF, Worth LL, et al. Interleukin (IL)12 and IL12 gene transfer upregulate Fas expression in human osteosareoma and breast cancer cells[J]. Cancer Res, 2001, 61(10): 4066-4071.
[16] Osaki M, Takeshita F, Sugimoto Y, et al. MicroRNA143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease13 expression[J]. Mol Ther, 2011, 19(6):1123-1130.
[17] Nagamori M, Kawaguchi S, Murakami M, et al. In vivo immunogenicity of osteosarcoma cells that express B71a, an alternatively spliced form of B71[J]. Anticancer Res, 2009, 22(4): 2009-2013.
[18] Posthumadeboer J, van Egmond PW, Helder MN, et al. Targeting JNKinteractingprotein1 (JIP1) sensitises osteosarcoma to doxorubicin[J]. Oncotarget, 2012, 3(10): 1169-1181.
[19] Zhang ZY, Wang LQ, Fu CF, et al. Combination of targeting geneviro therapy with recombinant Fowlpox viruses with HN and VP3 genes on mouse osteosarcoma[J]. Eur Rev Med Pharmacol Sci, 2013, 17(6): 767-776.
[20] Okumura K, Nakase M, Nakamura S, et al. Bax gene therapy for human osteosarcoma using cationic liposomes in vivo[J]. Once Rep, 2012, 17(4): 769-773. |